Improvement in seizure control and quality of life in medically refractory epilepsy patients converted from polypharmacy to monotherapy

Epilepsy and Behavior

Volumn 5, Issue 3, 2004, Pages 343-347

  Pirio Richardson, Sarah ^a   Farias, Sarah Tomaszewski ^a   Lima III, Anthony R ^a   Alsaadi, Taoufik M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Monotherapy; Polypharmacy; Quality of life; Refractory; Seizure

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE; LEPROSTATIC AGENT;

ADULT; AMNESIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; EPILEPSY; FEMALE; GENERAL CONDITION DETERIORATION; HEALTH STATUS; HUMAN; LEISURE; MALE; MEDICAL RECORD; MONOTHERAPY; OUTCOMES RESEARCH; POLYPHARMACY; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SEIZURE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; ATTITUDE TO HEALTH; COMPARATIVE STUDY; DRUG COMBINATION; MIDDLE AGED; PHARMACOKINETICS; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ADULT; ATTITUDE TO HEALTH; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; LEPROSTATIC AGENTS; MALE; MIDDLE AGED; POLYPHARMACY; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEIZURES; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 3042529016     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yebeh.2004.01.006     Document Type: Article

References (21)

1. Leppik I.E. Monotherapy and polypharmacy Neurology 55 Suppl. 3 2000 S25-S29
2. Leach J.P. Antiepileptic drugs: safety in numbers Seizure 9 2000 170-178
3. Stephen L.J. Brodie M.J. Seizure freedom with more than one antiepileptic drug Seizure 11 2002 349-351
4. Kwan P. Brodie M.J. Refractory epilepsy: a progressive, intractable but preventable condition? Seizure 11 2002 77-84
5. Kwan P. Brodie M. Epilepsy after the first drug fails: substitution or add-on? Seizure 9 2000 464-468
6. Bourgeois B. Reducing overtreatment Epilepsy Res. 52 2002 53-60
7. Ferrendelli J.A. Pharmacology of antiepileptic drug polypharmacy Epilepsia 40 Suppl. 5 1999 S81-S83
8. Deckers C. Hekster Y.A. Keyser A. et al. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study Epilepsia 42 2001 1387-1394
9. Matsuura M. Patient satisfaction with polypharmacy reduction in chronic epileptics Psychiatry Clin. Neurosci. 54 2000 249-253
10. Schmidt D. Reduction of two-drug therapy in intractable epilepsy Epilepsia 24 1983 368-376
11. Berg A.T. Langfitt J. Shinnar S. et al. How long does it take for partial epilepsy to become intractable? Neurology 60 2003 186-190
12. Gilliam F.G. Kuzniecky R. Faught E. et al. Patient-validated content of epilepsy-specific quality-of-life measurement Epilepsia 38 1997 233-236
13. Quigg M. Armstrong R.F. Farace E. et al. Quality of life outcome is associated with cessation rather than reduction of psychogenic nonepileptic seizures Epilepsy Behav. 3 2002 455-459
14. Perucca E. Gram L. Avanzini G. et al. Antiepileptic drugs as a cause of worsening seizures Epilepsia 39 1998 5-17
15. Albright P. Bruni J. Reduction of polypharmacy in epileptic patients Arch. Neurol. 42 1985 797-799
16. Cramer J.A. Glassman M. Rienzi V. The relationship between poor medication compliance and seizures Epilepsy Behav. 3 2002 338-342
17. Jallon P. The problem of intractability: the continuing need for new medical therapies in epilepsy Epilepsia 38 Suppl. 9 1997 S37-S42
18. Branford D. Bhaumik S. Duncan F. et al. A follow-up study of adults with learning disabilities and epilepsy Seizure 7 1998 469-472
19. Alsaadi T.M. Thieman C. Zusman E.E. Levetiracetam monotherapy for adults with localization-related epilepsy Epilepsy Behav. 3 2002 471-474
20. Sackellares J.C. Kwong W.J. Vuong A. et al. Lamotrigine monotherapy improves health-related quality of life in epilepsy: a double-blind comparison with valproate Epilepsy Behav. 3 2002 376-382
21. Gilliam FG, editor. Monotherapy in the management of epilepsy: study designs and results. Neurology 2003;60(11, Suppl. 4)